Protocol update and statistical analysis plan for CADENCE-BZ: A randomized clinical trial to assess the efficacy of sodium benzoate as an adjunctive treatment in early psychosis

Abstract

Background: CADENCE-BZ is a multi-centre, parallel-group, double-blind randomized controlled trial designed to examine the clinical efficacy and safety of an accessible food preservative, sodium benzoate, as an add-on treatment for patients with early psychosis. The original study protocol was published in 2017. Here, we describe the updated protocol along with the Statistical Analysis Plan (SAP) for the CADENCE-BZ trial prior to study completion. Methods and materials: Two important changes were made to the original protocol: (1) improvements to our statistical analysis plan permitted a reduction in sample size; and (2) a revision in the secondary outcomes with the intent of reducing redundancy and excluding those measures that were not appropriate as outcomes. Conclusions: We provide the updated SAP prior to the completion of the study with the intent of increasing the transparency of the data analyses for CADENCE-BZ. The final participants are currently completing the study and the results will be published in the near future. Trial registration: Australian New Zealand Clinical Trials Registry (ACTRN12615000187549). Registered on 26th February 2015.L6271062842019-04-16 <br />2019-05-14 <br />